What Is Sozinibercept? Definition and What Research Reports

Definition

Sozinibercept is an investigational biologic drug — a recombinant soluble receptor "trap" fusion protein — engineered to bind vascular endothelial growth factor C (VEGF-C) and vascular endothelial growth factor D (VEGF-D) and prevent them from activating their receptors. In published ophthalmology research it has been administered as an intravitreal injection and studied in combination with an established VEGF-A inhibitor such as aflibercept or ranibizumab, an approach described in trials of diabetic macular edema (PMID 39699889) and neovascular age-related macular degeneration (PMID 39999360). The term is definitional here: this entry describes what the molecule is and what the literature reports, not how anyone should use it.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical condition or treatment decision.

What Class of Molecule Is It, and Where Does It Come From?

Sozinibercept belongs to the family of recombinant fusion proteins — biologics produced in engineered cell lines rather than synthesised on a peptide synthesiser. Molecules in this class typically join a ligand-binding region derived from a natural receptor to an antibody fragment that improves stability, creating a soluble decoy that captures circulating growth factors before they reach cell-surface receptors. The suffix -cept in the international nonproprietary name signals exactly that design: receptor-domain-based traps carry it, distinguishing them from monoclonal antibodies (-mab) and antibody fragments (-fab).

Because of this, sozinibercept is not a peptide in the sense used for short synthetic sequences of a few dozen amino acids. It appears in peptide and protein glossaries because it sits in the broader category of protein-based therapeutics that act on growth-factor signalling, and because readers encountering the VEGF literature frequently meet it alongside smaller molecules. Anyone using this glossary to understand molecular classes should file sozinibercept under large biologic / fusion protein, not synthetic peptide.

The Target: VEGF-C and VEGF-D

The VEGF family contains several related growth factors. Most approved retinal drugs neutralise VEGF-A, the dominant driver of pathological vessel growth and vascular leakage. VEGF-C and VEGF-D are separate family members that signal through overlapping receptors and are associated with both blood-vessel and lymphatic-vessel biology. The scientific rationale explored in the published trials was that blocking VEGF-C and VEGF-D in addition to VEGF-A might address signalling that persists when VEGF-A alone is inhibited — which is why sozinibercept was evaluated as combination therapy rather than as a stand-alone agent in studies of diabetic macular edema (PMID 39699889) and polypoidal choroidal vasculopathy (PMID 40933661).

How the Term Is Used in Research

In published papers, "sozinibercept" almost always appears with three qualifiers that help readers interpret the context:

• Anti-VEGF-C/-D — the mechanistic descriptor used in the title of the polypoidal choroidal vasculopathy subgroup analysis (PMID 40933661).
• Combination therapy — the term used when sozinibercept was given together with a VEGF-A inhibitor, as in the phase 2b neovascular AMD subgroup analysis (PMID 39999360).
• Intravitreal — the route of administration in ophthalmic trials, meaning injection into the vitreous cavity of the eye, as in the phase 1b study conducted with aflibercept (PMID 39699889).

Search results for the name therefore cluster in retina and ophthalmology journals rather than in general peptide pharmacology. The word is also used loosely in secondary commentary as shorthand for "the VEGF-C/-D inhibition strategy," but in primary literature it refers specifically to the single investigational molecule.

What the Published Literature Reports

Phase 1b in Diabetic Macular Edema

A phase 1b dose-escalation study evaluated sozinibercept inhibition of vascular endothelial growth factors C and D given with aflibercept in eyes with diabetic macular edema, and the researchers designed it as a stepwise escalation to characterise tolerability and early signals rather than to prove efficacy (PMID 39699889). Dose-escalation designs of this kind enrol small numbers of participants in sequential cohorts, so the study was not powered to demonstrate differences in vision outcomes between groups (PMID 39699889).

Phase 2b Subgroup Analysis by Lesion Type in Neovascular AMD

A predefined analysis of a phase 2b study in neovascular age-related macular degeneration examined sozinibercept combination therapy with outcomes broken out by the type of choroidal neovascular lesion present at baseline, and the study reported results separately for those lesion subgroups (PMID 39999360). Subgroup analyses of this kind are hypothesis-generating: the researchers were exploring whether lesion morphology related to response, not establishing a confirmed treatment effect in any subgroup (PMID 39999360).

Phase IIb Subgroup Analysis in Polypoidal Choroidal Vasculopathy

A separate predefined subgroup analysis reported on sozinibercept combined with ranibizumab in participants with polypoidal choroidal vasculopathy, a variant form of neovascular macular disease (PMID 40933661). As with the lesion-type analysis, the researchers framed the polypoidal choroidal vasculopathy findings as a predefined subgroup within a larger phase IIb programme rather than as an independent confirmatory trial (PMID 40933661).

Published Studies at a Glance

Safety and Tolerability: What Studies Report

Early-phase dose-escalation studies exist primarily to characterise tolerability, and the phase 1b study of sozinibercept with aflibercept in diabetic macular edema was structured around that objective (PMID 39699889). Because the published subgroup analyses in neovascular AMD and polypoidal choroidal vasculopathy were secondary examinations of phase 2b data, the researchers reported them within the context of the parent trial rather than as dedicated safety studies (PMID 39999360, PMID 40933661). Readers who want specific adverse-event tables should consult the full reports directly; this glossary entry does not summarise numerical safety endpoints beyond what the cited titles and abstracts describe.

Regulatory and Practical Status

Sozinibercept is an investigational molecule. The published record consists of clinical trial reports and analyses conducted under research protocols in ophthalmology settings, including intravitreal administration in a hospital or clinic environment (PMID 39699889). It is not an over-the-counter product, not a research-chemical-style synthetic peptide, and not something that appears in general wellness contexts. Any statements about approval status should be checked against current regulatory databases, since the status of investigational biologics changes over time.

Limitations of the Current Evidence

• Phase and power. The available reports are phase 1b and phase 2b, and dose-escalation and subgroup designs are not powered for definitive efficacy conclusions (PMID 39699889).
• Subgroup caution. Predefined subgroup results, such as those reported by lesion type and in polypoidal choroidal vasculopathy, generate hypotheses rather than confirm them (PMID 39999360, PMID 40933661).
• Narrow setting. All cited work involved intravitreal administration in retinal disease; nothing in this literature speaks to other routes, other tissues, or non-ophthalmic uses.

Related Terms

• VEGF-A inhibitor — the established class (for example aflibercept, ranibizumab) that sozinibercept was combined with in the cited trials (PMID 40933661).
• Intravitreal injection — delivery directly into the eye's vitreous cavity.
• Fusion protein / receptor trap — the structural class sozinibercept belongs to.
• Neovascular AMD, diabetic macular edema, polypoidal choroidal vasculopathy — the retinal conditions in which it has been studied.

References

• Phase 1b Dose Escalation Study of Sozinibercept Inhibition of Vascular Endothelial Growth Factors C and D With Aflibercept for Diabetic Macular Edema (Translational Vision Science & Technology, 2024)
• Sozinibercept Combination Therapy for Neovascular Age-related Macular Degeneration: Phase 2b Study Subgroup Analysis by Lesion Type (Ophthalmic Surgery, Lasers & Imaging Retina, 2025)
• Sozinibercept (Anti-VEGF-C/-D) Combined with Ranibizumab for Polypoidal Choroidal Vasculopathy: Phase IIb Predefined Subgroup Analysis (Ophthalmology Science, 2025)